ミシガン州における多発性硬化症の臨床試験
ミシガン州内の拠点で、多発性硬化症に関する10件の研究が参加者を募集しています。
ミシガン州内の都市
公式研究テキスト（英語）
A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
- Northwest Neurology, Southfield
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/10/01更新 · NCT06782490A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- TG Therapeutics Investigational Trial Site, Ann Arbor
- TG Therapeutics Investigational Trial Site, Detroit
- TG Therapeutics Investigational Trial Site, Farmington
- 他2件
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/23更新 · NCT06433752Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
- Michigan Institute for Neurological Disorders- Site Number : 8400004, Farmington Hills
被験者募集中第3相
18歳〜60歳 · 全性別 · 2026/09/15更新 · NCT07325292RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Michigan, Ann Arbor
- Henry Ford Health, Novi
被験者募集中第2相
18歳〜80歳 · 全性別 · 2026/09/15更新 · NCT07002034A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, Ann Arbor
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06680037Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
- Kahana Oculoplastic and Orbital Surgery, Livonia
被験者募集中第3相
18歳〜50歳 · 全性別 · 2026/08/14更新 · NCT07623668A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
- Michigan Institute of Neurological, Farmington Hills
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/07/29更新 · NCT07225504Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
- University of Michigan, Ann Arbor
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/07/17更新 · NCT05269628A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
- Quest Research Institute, Farmington Hills
被験者募集中第2相
18歳〜55歳 · 全性別 · 2026/06/15更新 · NCT06735248Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
- Wayne State University, Detroit
被験者募集中観察研究
18歳〜60歳 · 全性別 · 2022/06/06更新 · NCT04458688ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。